Human drug abuse liability: testing times ahead

Disaggregating the liability for drug abuse.

It is consensually accepted that the liability for developing a substance abuse disorder is not the same for all individuals in the population. Only marginal progress has been made, however, in determining the factors responsible for the variation in the liability to drug abuse, encompassing interacting biological, behavioral, and environmental processes. Since variation in the liability has a ...

Testing for Abuse Liability of Drugs in Humans, 92

Testing Drugs for Physical Dependence Potential and Abuse Liability, 52

NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination...

Abuse liability of buprenorphine--a study among experienced drug users.

Six male post-detoxified opiate dependent subjects were evaluated for abuse liability of buprenorphine (0.6 mg), morphine (16 mg), pentazocine (30 mg) and distilled water (placebo) intramuscular injection in a single blind cross-over random order. Subjective states, drug discrimination, drug linking, sedation and euphoria were assessed at pre-injection, 30 min and 4 hrs post-injection. Buprenor...

Sector Overview Ocular Drug Delivery Technologies : Exciting times Ahead

The 2010 global cost of vision loss was nearly US$3 trillion (£2 trillion) for the 733 million people living with low vision and blindness,1 with this number expected to increase significantly due to the aging population and the increasing incidence of metabolic disorders such as diabetes. This makes eye disorders one of the costliest health conditions worldwide. The major blinding disorders cu...